HER2 Support Group Forums - The Lancet Publishes Results From Pivotal Study Of Eisai's Halaven® In Patients With

HER2 Support Group Forums (https://her2support.org/vbulletin/index.php)

- Breast Cancer Newsfeed (https://her2support.org/vbulletin/forumdisplay.php?f=52)

- - The Lancet Publishes Results From Pivotal Study Of Eisai's Halaven® In Patients With (https://her2support.org/vbulletin/showthread.php?t=49115)

News	03-05-2011 03:15 AM

The Lancet Publishes Results From Pivotal Study Of Eisai's Halaven® In Patients With

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that results from a pivotal study with HALAVEN® (eribulin mesylate), a novel anticancer agent discovered and developed by the company, will be published in the medical journal The Lancet1)...

More...

All times are GMT -7. The time now is 05:25 PM.